TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05962255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide intravenous infusion
Description: At baseline, patients will receive a standardised dose of furosemide 1mg/kg (half of the dose administered as bolus and half as in 2h infusion).~At the 6th and the 12th hour of the study patients will be reassessed and the need for additional diuretics.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide intravenous infusion
Description: At baseline, patients will receive a standardised dose of furosemide 1mg/kg (half of the dose administered as bolus and half as in 2h infusion).~At the 6th and the 12th hour of the study patients will be reassessed and the need for additional diuretics.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continous intravenous infusion of 0.9% Sodium Chloride solution
Description: Continuous 48h infusion of 0.9% sodium chloride at a fixed rate v= 83 ml/h x 24h = 2l/24h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continous intravenous infusion of 5% Glucose solution
Description: Continuous 48h infusion of 5% Glucose at a fixed rate v= 83 ml/h x 24h = 2l/24h
Study: NCT05535114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga-resistance exercise
Description: Breathing exercise (5 minutes), flexibility (5 minutes), resistance exercise (20 minutes), relaxation \& meditation (10 minutes).
Study: NCT05208723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress and emotion management
Description: The handbook materials and lay helper scripts are based on principles of Acceptance and Commitment Therapy (ACT), and aims to enhance psychological flexibility. Psychological flexibility reflects how a person adapts to fluctuating situational demands, reconfigures mental resources, shifts perspective, and balances competing needs. ACT teaches alternative methods to accommodate difficult thoughts and feelings, primarily through mindfulness techniques. At the same time, ACT also focuses on guiding participants to live in ways consistent with their personal values.
Study: NCT05376722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pamiparib
Description: pamiparib 40 mg orally, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone
Description: biraterone acetate 1000 mg orally, once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: prednisone acetate tablets (prednisone) 5 mg, once a day
Study: NCT05572879

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EuCorVac-19
Description: COVID-19 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EuCorVac-19
Description: COVID-19 vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAdOx1 nCoV-19
Description: COVID-19 vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAdOx1 nCoV-19
Description: COVID-19 vaccine
Study: NCT06371664

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Tray (1 mm)
Description: General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of conventional individualized bleaching trays (trimmed 1 mm above the gingival margin) and a position-finder tray of both arches. Application of the bleaching gel in the bleaching trays during 6-8 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Tray (3 mm)
Description: General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of extended individualized bleaching trays (trimmed 3 mm above the gingival margin) and a position-finder tray of both arches. Application of the bleaching gel in the bleaching trays during 6-8 hours
Study: NCT04850612

Intervention type: OTHER
Intervention: Survey
Description: Delphi Survey on core outcomes, CSDH definition and data elements

Intervention type: OTHER
Intervention: Survey
Description: Delphi Survey on core outcomes, CSDH definition and data elements
Study: NCT05152277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531
Description: Administered SC once

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered SC once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531
Description: Administered SC for multiple dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered SC for multiple dose
Study: NCT04724304

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Real-Time Myocardial Echocardiography (RTMPE)
Description: Uses sound waves (ultrasound) to produce an images of the heart. During RTMPE a microbubble contrast agent is administered through an intravenous line (IV) to make the images of your heart clearer.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic resonance image (MRI)
Description: Imaging that focuses on the heart or blood vessels to assess size and function of the heart's chambers, thickness and movement of the walls of the heart, and blood flow in the blood vessels.
Study: NCT04348539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training
Description: 32 sessions will be held twice a week, with each session taking an average of 45 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training
Description: 32 sessions will be held twice a week, with each session taking an average of 45 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training
Description: 32 sessions will be held twice a week, with each session taking an average of 45 minutes
Study: NCT05688072

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: trunk oriented exercise
Description: trunk oriented exercises include: stretching exercises, stabilization exercises (active or active-assisted), arm exercises in fixed trunk position, trunk-oriented exercises (active or active-assisted), trunk mobilization (sitting and lying position), and functional reaching exercises with different ranges of motion in shoulder elevation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: whole body vibration
Description: WBV application technique. The children assume a full squatting position on a vibration platform. The apparatus will set at a frequency of 30 Hz, an amplitude of 2 mm, and a duration of 5 min. The children were instructed to remain in squatting position after the vibration started and to report any discomfort that arose. At the end of 5 min, the vibration turned off automatically. Thereafter, the children rested for 1 min. They were then asked to stand on the vibration platform while supported by the therapist for 5 min, with the same parameters as those used in the squatting position. The total time of application of WBV in each session was 10 min.
Study: NCT04781907

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue Expansion
Description: Tissue expanders are used to increase the soft tissue envelope after mastectomy to provide adequate and healthy coverage of prosthetic breast implants.
Study: NCT05966493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lufepirsen
Description: Lufepirsen is an unmodified connexin43 antisense oligonucleotide.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Matching vehicle without lufepirsen.
Study: NCT06435182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT202 conc 0.5%
Description: Apply 1-2 drops of OT202 0.5% solution into the conjunctival sac. three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT202 conc 0.1%
Description: Apply 1-2 drops of OT202 0.1% solution into the conjunctival sac. three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Apply 1-2 drops of placebo solution into the conjunctival sac. three times daily
Study: NCT05034458

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crohn's disease exclusion diet
Description: Patients will receive, in addition to their normal treatment, polymeric formula + diet
Study: NCT05911464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10386
Description: Starting dose 10 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of HS-10386, until a maximum tolerated dose (MTD) or maximum applicable dose (MAD) is defined
Study: NCT06315244

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US Guided Perineural Injection and Neuroprolotherapy
Description: Participants will receive an ultrasound-guided injection of a solution into the sacrotuberous ligament and the sensory innervation area of the perforating cutaneous nerve.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: US Guided Perineural Injection and Neuroprolotherapy
Description: Participants will receive an ultrasound-guided injection of a solution into the sacrotuberous ligament and the sensory innervation area of the perforating cutaneous nerve.
Study: NCT06445894

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Repetitive Transcranial Magnetic Stimulation
Description: rTMS is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The first dorsal interossesous (FDI) muscle of the left motor cortex will be targeted using neuronavigation software.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Repetitive Transcranial Magnetic Stimulation
Description: rTMS is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The first dorsal interossesous (FDI) muscle of the left motor cortex will be targeted using neuronavigation software.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: A sham coil will be utilized for the sham rTMS condition. It is important to note that from the participant perspective, the sham stimulation will feel and sound identical to active. The location and all other parameters of Sham rTMS will be identical to Active rTMS.
Study: NCT05366192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir and ritonavir stage 1
Description: Nirmatrelvir 150mg qd (another 75mg will be supplied after hemodialysis treatment) and ritonavir 100mg bid everyday for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir and ritonavir stage 2
Description: Nirmatrelvir 300mg qd (another 150mg will be supplied after hemodialysis treatment) and ritonavir 100 bid everyday for 5 days.
Study: NCT05133544

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endocuff with AI
Description: Use of endocuff with computer assisted polyp detection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AI alone
Description: Use of computer assisted polyp detection
Study: NCT06299813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bentelan
Description: The experimental treatment group will be administered betamethasone 0.1 mg per kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo used in the study will consist of 100 ml of purified water (PPI BBU).
Study: NCT06067282

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microteaching
Description: This program selects five kinds of core teaching skills for training, and the training program is extracted in Microteaching .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microteaching
Description: This program selects five kinds of core teaching skills for training, and the training program is extracted in Microteaching .
Study: NCT05596786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: One course of IV rituximab consisting of a first infusion of 1000 mg (500 mL solution) rituximab (day 1), and a second infusion of 1000 mg (500 mL solution) rituximab two weeks later (day 15)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One course of IV placebo of rituximab consisting of a first infusion of 500 mL of saline (0.9% sodium chloride) infusion (day 1), and a second infusion of 500 mL of saline infusion two weeks later (day 15)
Study: NCT04430283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDY-5301
Description: FDY-5301 is Sodium Iodide administered as an isotonic solution for intravenous injection with a concentration of 7.2 mg/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDY-5301
Description: FDY-5301 is Sodium Iodide administered as an isotonic solution for intravenous injection with a concentration of 7.2 mg/ml.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is delivered as a single dose, non-reserved liquid parenteral consisting of a formulation matched compendial saline.
Study: NCT04944615

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The guidewire successfully passed the CTO lesion
Description: The successful passage of the guide wire through the CTO lesion was defined as: the guide wire successfully passed through the CTO lesion and reached the distal true lumen as confirmed by angiography.~Aspirin load dose (300 mg), clopidogrel load dose (300 mg), or ticagrelor load dose (180 mg) is recommended for all subjects prior to stent implantation and is recommended to be taken at least 6 hours prior to surgery.
Study: NCT05825599

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydroxypropyl methylcellulose eye drops
Description: Hydroxypropyl methylcellulose (HPMC)-based eyedrops
Study: NCT04693923

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid challenge
Description: Fluid challenge according to the assigned group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluid challenge
Description: Fluid challenge according to the assigned group
Study: NCT04238988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized antibody used in cancer immunotherapy. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes.
Study: NCT05816694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAB-Paclitaxel plus Cisplatin
Description: NAB-Paclitaxel will be administered as 125 mg/m2 IV infusion on Day 1 、Day8 of each 3-week cycle. Cisplatin will be administered as 75 mg/m2 IV infusion on Day 1 of each 3-week cycle. Patients will receive maximum of 4 cycles if they do not meet the criteria for removal from the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin plus Epirubicin plus Cyclophosphamide
Description: Cisplatin was administered as 50 mg/m2 IV infusion on Day 1; Epirubicin was administered as 75 mg/m2 IV infusion on Day 1; Cyclophosphamide was administered as 500 mg/m2IV infusion on Day 1 of each 3-week cycle.Patients will receive maximum of 4 cycles if they do not meet the criteria for removal from the study.
Study: NCT04238988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy medication
Study: NCT06314165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music medicine practice
Description: Music medicine will be applied
Study: NCT05597917

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trabectedin
Description: Patients will receive standard trabectedin 1.5 mg/m2 as a 24-hour central intravenous (IV) infusion on day 1, q d 22 x until disease progression or contraindications against further application.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Patients will receive standard trabectedin 1.5 mg/m2 as a 24-hour central intravenous (IV) infusion on day 1, q d 22 x until disease progression or contraindications against further application.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tTF-NGR
Description: Patients will receive standard trabectedin according to arm 1 plus the safe dose according to safety run-in part of tTF-NGR (1-hour ratecontrolled infusion, port central venous access, 0.9 % NaCl ad 100 mL) per day for 4 or lower number of consecutive days following each trabectedin cycle (within 1 hour interval between end of trabectedin infusion and tTF-NGR: e.g.: trabectedin on monday 8 am to tuesday 8 am followed by tTF-NGR on tuesday 9 am and on the following days, q d 22 x until disease progression or contraindications against further application.
Study: NCT06315582

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removal of uterine septum with hysteroscopic scissors without electrosurgery.
Description: Hysteroscopic septoplasty utilizing scissors without electrosurgery followed by hysteroscopic morcellation of residual tissue

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysteroscopic septoplasty utilizing bipolar electrosurgery
Description: Hysteroscopic septoplasty utilizing bipolar electrosurgery
Study: NCT05825196

Intervention type: DIAGNOSTIC_TEST
Intervention: tumor tissue and blood tests
Description: In this study, we need to collect an extra tube of blood for routine testing and the tissue after completion of pathological examination.

Intervention type: DIAGNOSTIC_TEST
Intervention: tumor tissue and blood tests
Description: In this study, we need to collect an extra tube of blood for routine testing and the tissue after completion of pathological examination.
Study: NCT04944615

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The guidewire successfully passed the CTO lesion
Description: The successful passage of the guide wire through the CTO lesion was defined as: the guide wire successfully passed through the CTO lesion and reached the distal true lumen as confirmed by angiography.~Aspirin load dose (300 mg), clopidogrel load dose (300 mg), or ticagrelor load dose (180 mg) is recommended for all subjects prior to stent implantation and is recommended to be taken at least 6 hours prior to surgery.
Study: NCT04238988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: Chemotherapy medication
Study: NCT05825196

Intervention type: DIAGNOSTIC_TEST
Intervention: tumor tissue and blood tests
Description: In this study, we need to collect an extra tube of blood for routine testing and the tissue after completion of pathological examination.
Study: NCT04781387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRS3123
Description: Study drug dosed at 200 mg PO BID (treatment arm A) or 400 mg PO BID (treatment arm B) for total of 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRS3123
Description: Study drug dosed at 200 mg PO BID (treatment arm A) or 400 mg PO BID (treatment arm B) for total of 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Active comparator is administered 125 mg PO QID
Study: NCT05502965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary pattern
Description: Reprocessed and intolerant foods were removed from the dietary pattern, and the food were cooked at home for experimental subjects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EEN
Description: All energy and nutrients are obtained from exclusive enteral nutrition.
Study: NCT06092385

Intervention type: OTHER
Intervention: Data collection
Description: Clinical assessment and blood sampling at day of inclusion and in 6- monthly intervals for stable cirrhotic patients; at day of inclusion and on days 3, 7, 14 and 28 for acute decompensation or acute-on-chronic liver failure patients; assessment of clinical, psychosocial/behavioural and patient-reported data in parallel with blood sampling;~* Biobanking of PBMCs and serum/plasma samples~* Biobanking of other biological material if sampled for clinical reasons (liver biopsies, ascites, urine, gut mucosa, lymph nodes)

Intervention type: OTHER
Intervention: Data collection
Description: Clinical assessment and blood sampling at day of inclusion and in 6- monthly intervals for stable cirrhotic patients; at day of inclusion and on days 3, 7, 14 and 28 for acute decompensation or acute-on-chronic liver failure patients; assessment of clinical, psychosocial/behavioural and patient-reported data in parallel with blood sampling;~* Biobanking of PBMCs and serum/plasma samples~* Biobanking of other biological material if sampled for clinical reasons (liver biopsies, ascites, urine, gut mucosa, lymph nodes)
Study: NCT05249530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic spinal adjustment
Description: Chiropractic spinal adjustment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-force simulation
Description: Non-force simulation
Study: NCT05698394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: 0.2 mg/kg S-ketamine in 20 ml normal saline will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 ml normal saline will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth.
Study: NCT06622434

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: immunization
Description: One month after completion of concurrent radiochemotherapy, patients will be immunized during the adjuvant phase of monthly temozolomide with subcutaneous injections of the vaccine formulation (D0, W2, W4, W6, and then every 2 months until progression) consisting of 2 tumor antigens (TERT and PTPRZ1) adjuvanted with synthetic melanin and a TLR9 agonist (CpG-ODN).
Study: NCT06183489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: Elranatamab will be administered via a subcutaneous injection (SC)
Study: NCT06630533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baduanjin Exercise Group
Description: Baduanjin exercises (Eight-Part Exercises or Eight-Part Brocades), an important part of Qigong, consist of eight postures (1-holding the hands high with palms up, 2- posing as an archer shooting, 3- holding one arm aloft, 4- looking backwards, 5- swinging the head and lowering the body, 6- moving the hands down the back and legs and touching the feet, 7- thrusting the fists and making the eyes glare, and 8- raising and lowering the heels).
Study: NCT06714695

Intervention type: DRUG
Group type: OTHER
Intervention: Chitosan
Description: chitosan mouthwash